Cowan Elvia's most recent trade in Vaxcyte Inc was a trade of 17,961 Stock Option (right to buy) done . Disclosure was reported to the exchange on Feb. 27, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Vaxcyte Inc | Elvia Cowan | SVP, FINANCE | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2025 | 17,961 | 17,961 | - | - | Stock Option (right to buy) | |
| Vaxcyte Inc | Elvia Cowan | SVP, FINANCE | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2025 | 5,379 | 24,673 | - | 0 | Common Stock | |
| Vaxcyte Inc | Elvia Cowan | SVP, FINANCE | Payment of exercise price or tax liability using portion of securities received from the company at price $ 72.10 per share. | 27 Feb 2025 | 325 | 24,106 | - | 72.1 | 23,433 | Common Stock |
| Vaxcyte Inc | Elvia Cowan | SVP, FINANCE | Payment of exercise price or tax liability using portion of securities received from the company at price $ 73.02 per share. | 27 Feb 2025 | 242 | 24,431 | - | 73.0 | 17,671 | Common Stock |
| Vaxcyte Inc | Cowan Elvia | SVP, FINANCE | Exercise or conversion of derivative security received from the company (such as an option) at price $ 25.92 per share. | 16 Dec 2024 | 7,716 | 19,294 | - | 25.9 | 199,999 | Common Stock |
| Vaxcyte Inc | Elvia Cowan | SVP, FINANCE | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Dec 2024 | 7,716 | 106,284 | - | - | Stock Option (right to buy) | |
| Vaxcyte Inc | Elvia Cowan | SVP, FINANCE | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Nov 2024 | 11,900 | 11,900 | - | - | Performance Stock Option (right to buy) | |
| Vaxcyte Inc | Elvia Cowan | SVP, FINANCE | Exercise or conversion of derivative security received from the company (such as an option) at price $ 25.92 per share. | 03 Sep 2024 | 5,000 | 17,723 | - | 25.9 | 129,600 | Common Stock |
| Vaxcyte Inc | Elvia Cowan | SVP, FINANCE | Sale of securities on an exchange or to another person at price $ 107.67 per share. | 03 Sep 2024 | 5,000 | 12,723 | - | 107.7 | 538,350 | Common Stock |
| Vaxcyte Inc | Elvia Cowan | SVP, FINANCE | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Sep 2024 | 5,000 | 114,000 | - | - | Stock Option (right to buy) | |
| Vaxcyte Inc | Elvia Cowan | SVP, FINANCE | Payment of exercise price or tax liability using portion of securities received from the company at price $ 110.15 per share. | 03 Sep 2024 | 1,145 | 11,578 | - | 110.2 | 126,122 | Common Stock |
| Vaxcyte Inc | Elvia Cowan | SVP, FINANCE | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jul 2024 | 5,000 | 119,000 | - | - | Stock Option (right to buy) | |
| Vaxcyte Inc | Elvia Cowan | SVP, FINANCE | Sale of securities on an exchange or to another person at price $ 85.00 per share. | 16 Jul 2024 | 5,000 | 12,723 | - | 85 | 425,000 | Common Stock |
| Vaxcyte Inc | Elvia Cowan | SVP, FINANCE | Exercise or conversion of derivative security received from the company (such as an option) at price $ 25.92 per share. | 16 Jul 2024 | 5,000 | 17,723 | - | 25.9 | 129,600 | Common Stock |
| Vaxcyte Inc | Elvia Cowan | SVP, FINANCE | Sale of securities on an exchange or to another person at price $ 80.00 per share. | 08 Jul 2024 | 5,000 | 12,723 | - | 80 | 400,000 | Common Stock |
| Vaxcyte Inc | Elvia Cowan | SVP, FINANCE | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jul 2024 | 5,000 | 124,000 | - | - | Stock Option (right to buy) | |
| Vaxcyte Inc | Elvia Cowan | SVP, FINANCE | Exercise or conversion of derivative security received from the company (such as an option) at price $ 25.92 per share. | 08 Jul 2024 | 5,000 | 17,723 | - | 25.9 | 129,600 | Common Stock |
| Vaxcyte Inc | Elvia Cowan | SVP, FINANCE | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Feb 2024 | 25,000 | 25,000 | - | - | Stock Option (right to buy) | |
| Vaxcyte Inc | Elvia Cowan | SVP, FINANCE | Exercise or conversion of derivative security received from the company (such as an option) at price $ 25.92 per share. | 29 Feb 2024 | 11,000 | 24,158 | - | 25.9 | 285,120 | Common Stock |
| Vaxcyte Inc | Elvia Cowan | SVP, FINANCE | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Feb 2024 | 11,000 | 129,000 | - | - | Stock Option (right to buy) | |
| Vaxcyte Inc | Elvia Cowan | SVP, FINANCE | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Feb 2024 | 5,400 | 13,158 | - | 0 | Common Stock | |
| Vaxcyte Inc | Elvia Cowan | SVP, FINANCE | Sale of securities on an exchange or to another person at price $ 74.90 per share. | 29 Feb 2024 | 4,901 | 12,480 | - | 74.9 | 367,085 | Common Stock |
| Vaxcyte Inc | Elvia Cowan | SVP, FINANCE | Sale of securities on an exchange or to another person at price $ 73.69 per share. | 29 Feb 2024 | 4,455 | 17,381 | - | 73.7 | 328,284 | Common Stock |
| Vaxcyte Inc | Elvia Cowan | SVP, FINANCE | Sale of securities on an exchange or to another person at price $ 73.08 per share. | 29 Feb 2024 | 2,322 | 21,836 | - | 73.1 | 169,701 | Common Stock |
| Vaxcyte Inc | Elvia Cowan | SVP, FINANCE | Payment of exercise price or tax liability using portion of securities received from the company at price $ 71.55 per share. | 29 Feb 2024 | 324 | 12,156 | - | 71.5 | 23,182 | Common Stock |
| Vaxcyte Inc | Elvia Cowan | SVP, Finance | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 43,500 | 43,500 | - | - | Stock Option (right to buy) | |
| Vaxcyte Inc | Elvia Cowan | SVP, Finance | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 7,250 | 7,250 | - | 0 | Common Stock |